Pasar al contenido principal

Interrelación del microbioma y la inmunidad entrenada para el desarrollo de inmunoterapias basadas en inmunidad entrenada

CPP2021-008310

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Transferencia de Conocimiento
Convocatoria Proyectos en Colaboración Público-Privada
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INMUNOTEK SL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Oxidative phosphorylation selectively orchestrates tissue macrophage homeostasis

  • Wculek, Stefanie K
  • Heras-Murillo, Ignacio
  • Mastrangelo, Annalaura
  • Mañanes, Diego
  • Galán, Miguel
  • Miguel, Verónica
  • Curtabbi, Andrea
  • Barbas, Coral
  • Chandel, Navdeep S
  • Enríquez, José Antonio
  • Lamas Peláez, Santiago
  • Sancho, David
In vitro studies have associated oxidative phosphorylation (OXPHOS) with anti-inflammatory macrophages, whereas pro-inflammatory macrophages rely on glycolysis. However, the metabolic needs of macrophages in tissues (TMFs) to fulfill their homeostatic activities are incompletely understood. Here, we identified OXPHOS as the highest discriminating process among TMFs from different organs in homeostasis by analysis of RNA-seq data in both humans and mice. Impairing OXPHOS in TMFs via Tfam deletion differentially affected TMF populations. Tfam deletion resulted in reduction of alveolar macrophages (AMs) due to impaired lipid-handling capacity, leading to increased cholesterol content and cellular stress, causing cell-cycle arrest in vivo. In obesity, Tfam depletion selectively ablated pro-inflammatory lipid-handling white adipose tissue macrophages (WAT-MFs), thus preventing insulin resistance and hepatosteatosis. Hence, OXPHOS, rather than glycolysis, distinguishes TMF populations and is critical for the maintenance of TMFs with a high lipid-handling activity, including pro-inflammatory WAT-MFs. This could provide a selective therapeutic targeting tool., This project was supported by the “la Caixa” Foundation (ID 100010434) Postdoctoral Junior Leader Fellowship code LCF/BQ/PR20/11770008 (S.K.W.); “la Caixa” Foundation (ID 100010434) INPhINIT Fellowship code LCF/BQ/IN17/11620074 (I.H.-M.); Spanish Ministry of Education FPU fellowship code FPU20/01418 (M.G.); Ministerio de Ciencia e Innovación (MCIN) PID2019-104233RB-100/AEI/10.13039/501100011033 (S.L.); and NIH grants P01AG049665-08, RO1A148190, and P01HL154998 (N.S.C.). The J.A.E. laboratory is supported by the CNIC and a grant by Ministerio de Ciencia, Innovación y Universidades (MCNU); Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) (RTI2018-099357-B-I00); the Biomedical Research Networking Center on Frailty and Healthy Ageing (CIBERFES-ISCiii-CB16/10/00289); and the HFSP agency (RGP0016/2018). Work in the D.S. laboratory is funded by the CNIC; by the European Union’s Horizon 2020 research and innovation program under grant agreement ERC-2016-Consolidator grant 725091; by Spanish Ministerio de Ciencia e Innovación PID2019-108157RB/AEI/ and CPP2021-008310/AEI/10.13039/501100011033; by Comunidad de Madrid (P2022/BMD-7333 INMUNOVAR-CM); and by “la Caixa” Foundation (LCF/PR/HR20/00075 and LCF/PR/HR22/00253). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the MICINN, and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MCIN/AEI/10.13039/501100011033)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2020-001041-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung

  • Moreo, Eduardo
  • Jarit-Cabanillas, Aitor
  • Robles-Vera, Iñaki
  • Uranga, Santiago
  • Guerrero, Claudia
  • Gómez, Ana Belén
  • Mata-Martínez, Pablo
  • Minute, Luna
  • Araujo-Voces, Miguel
  • Felgueres, María José
  • Esteso, Gloria
  • Uranga-Murillo, Iratxe
  • Arias, Maykel
  • Pardo, Julián
  • Martín, Carlos
  • Valés-Gómez, Mar
  • Del Fresno, Carlos
  • Sancho, David
  • Aguiló, Nacho
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-023-41768-8., Intravesical administration of Bacillus Calmette-Guérin (BCG) was one of the first FDA-approved immunotherapies and remains a standard treatment for bladder cancer. Previous studies have demonstrated that intravenous (IV) administration of BCG is well-tolerated and effective in preventing tuberculosis infection in animals. Here, we examine IV BCG in several preclinical lung tumor models. Our findings demonstrate that BCG inoculation reduced tumor growth and prolonged mouse survival in models of lung melanoma metastasis and orthotopic lung adenocarcinoma. Moreover, IV BCG treatment was well-tolerated with no apparent signs of acute toxicity. Mechanistically, IV BCG induced tumor-specific CD8+ T cell responses, which were dependent on type 1 conventional dendritic cells, as well as NK cell-mediated immunity. Lastly, we also show that IV BCG has an additive effect on anti-PD-L1 checkpoint inhibitor treatment in mouse lung tumors that are otherwise resistant to anti-PD-L1 as monotherapy. Overall, our study demonstrates the potential of systemic IV BCG administration in the treatment of lung tumors, highlighting its ability to enhance immune responses and augment immune checkpoint blockade efficacy., This work was supported by MCIN/AEI/10.13039/501100011033 [grants number RTI2018-097625-B-I00 and PID2022-138624OB-I00], Gobierno de Aragón [grant number LMP50_21] and Asociación Española Contra el Cáncer (AECC) [grant number IDEAS211042AGUI]. NA was the prin- cipal investigator of all these grants. This research was supported by CIBER -Consorcio Centro de Investigación Biomédica en Red- (Groups CB06/06/0020 and CB21/13/00087), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – European Regional Development Fund. DS laboratory is funded by the CNIC; by the European Union’s Horizon 2020 research and innovation program under grant agreement ERC-2016-Consolidator Grant 725091; by MCIN PID2019-108157RB MCIN/AEI/10.13039/501100011033 and CPP2021- 008310 MCIN/AEI/10.13039/501100011033 Unión Europea Next Gen- erationEU/PRTR; by Comunidad de Madrid (P2022/BMD-7333 INMU- NOVAR-CM); and by “la Caixa” Foundation (LCF/PR/HR20/00075 and LCF/PR/HR22/00253).The laboratory of C.d.F. is funded by Instituto de Salud Carlos III (ISCIII) through the projects CP20/00106 and PI21/01178 and co-funded by the European Union. The laboratory of M.V-G. is fun- ded by Spanish Ministry of Science and Innovation [grant number PID2021-123795OB-I00]. C.G. has a pre-doctoral fellowship from Gobierno de Aragón. M.J.F. is PhD Candidate at the Autonomous Madrid University., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

pDCs amplify tissue-resident memory CD8+ T cell responses during viral reinfection

  • Hernández-García, Elena
  • Galán, Miguel
  • Khouili, Sofía C
  • Moya-Ruiz, Elena
  • Redondo-Urzainqui, Ana
  • Cueto, Francisco J
  • Martínez-Cano, Saraí
  • Rodrigo-Tapias, Manuel
  • Tomasello, Elena
  • Mañes, Santos
  • Dalod, Marc
  • Sancho, David
  • Iborra, Salvador
Resident memory CD8+ T cells (Trms) are essential for protecting barrier nonlymphoid tissues (NLTs) against reinfection, yet the involvement of dendritic cells (DCs) in this process and the nature of Trm-DC interactions within these tissues remain poorly understood. Our study demonstrates that upon reactivation, memory CD8+ T cells located in the skin-independently of circulating memory counterparts-initiate the infiltration and maturation of plasmacytoid DCs (pDCs) in the tissue. This, in turn, promotes the maturation of conventional type 1 DCs (cDC1s) through type I IFN (IFN-I) signaling in a pDC-dependent manner. Depletion of pDCs or blocking IFN-I signaling disrupts this axis, severely impairing Trm-driven protection against secondary infections with vaccinia virus (VACV) in the skin. Notably, this pDC-dependent, IFN-I-mediated pathway is also essential for Trm-mediated protection against secondary respiratory infections with influenza A virus (IAV). Our findings uncover a crucial collaboration between Trm, pDCs, and cDC1s, offering new insights for enhancing vaccines., Funder(s): Agencia Estatal de Investigación Award Id(s): PID2021-125415OB-I00 Funder(s): European Regional Development Fund Funder(s): Ministerio de Ciencia e Innovación Award Id(s): PID2022-137712OB-I00 , CPP2021-008310 , CPP2022-009762 , PID2023-147125OB-I00 Funder(s): Comunidad de Madrid Award Id(s): P2022/BMD-7333 INMUNOVAR-CM , PIPF-2022/SAL-GL-24581 , PIPF-2023/SAL-GL-29932 Funder(s): Centro Nacional de Investigaciones Cardiovasculares Funder(s): Scientific Foundation, Spanish Association Against Cancer Award Id(s): AECC-PRYGN246642SANC Funder(s): Worldwide Cancer Research Award Id(s): WWCR-25-0080 Funder(s): European Union Award Id(s): ERC-2023-PoC Funder(s): la Caixa Foundation Award Id(s): LCF/PR/HR23/52430012 , LCF/PR/HR22/52420019 Funder(s): Ministry of Science, Innovation, and Universities Award Id(s): CD21/00185 , PRE2019-087509 , FPU20/01418 , FPU16/03142 Funder(s): Instituto de Salud Carlos III Funder(s): Pro CNIC Foundation, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Imidazole propionate is a driver and therapeutic target in atherosclerosis

  • Mastrangelo, Annalaura
  • Robles-Vera, Iñaki
  • Mañanes, Diego
  • Galán, Miguel
  • Femenía-Muiña, Marcos
  • Redondo-Urzainqui, Ana
  • Barrero-Rodríguez, Rafael
  • Papaioannou, Eleftheria
  • Amores-Iniesta, Joaquín
  • Devesa, Ana
  • Lobo-González, Manuel
  • Carreras, Alba
  • Beck, Katharina R.
  • Ivarsson, Sophie
  • Gummesson, Anders
  • Georgiopoulos, Georgios
  • Rodrigo-Tapias, Manuel
  • Martínez-Cano, Sarai
  • Fernández-López, Ivan
  • Nuñez, Vanessa
  • Ferrarini, Alessia
  • Inohara, Naohiro
  • Stamatelopoulos, Kimon
  • Benguría, Alberto
  • Cibrian, Danay
  • Sánchez-Madrid, Francisco
  • Alonso-Herranz, Vanesa
  • Dopazo, Ana
  • Barbas, Coral
  • Vázquez, Jesús
  • López, Juan Antonio
  • González-Martín, Alicia
  • Nuñez, Gabriel
  • Stellos, Konstantinos
  • Bergström, Göran
  • Bäckhed, Fredrik
  • Fuster, Valentín
  • Ibañez, Borja
  • Sancho, David
Atherosclerosis is the main underlying cause of cardiovascular diseases. Its prevention is based on the detection and treatment of traditional cardiovascular risk factors1. However, individuals at risk for early vascular disease often remain unidentified2. Recent research has identified new molecules in the pathophysiology of atherosclerosis3, highlighting the need for alternative disease biomarkers and therapeutic targets to improve early diagnosis and therapy efficacy. Here, we observed that imidazole propionate (ImP), produced by microorganisms, is associated with the extent of atherosclerosis in mice and in two independent human cohorts. Furthermore, ImP administration to atherosclerosis-prone mice fed with chow diet was sufficient to induce atherosclerosis without altering the lipid profile, and was linked to activation of both systemic and local innate and adaptive immunity and inflammation. Specifically, we found that ImP caused atherosclerosis through the imidazoline-1 receptor (I1R, also known as nischarin) in myeloid cells. Blocking this ImP–I1R axis inhibited the development of atherosclerosis induced by ImP or high-cholesterol diet in mice. Identification of the strong association of ImP with active atherosclerosis and the contribution of the ImP–I1R axis to disease progression opens new avenues for improving the early diagnosis and personalized therapy of atherosclerosis., M. O. Garmendia for assistance with the metadata from volunteers; members of the D.S. laboratory for help with discussions and critical reading of the manuscript; and the CNIC facilities, foremost the animal, cellomics, histology, metabolomics, genomics, microscopy, clinical trial and bioinformatics facilities, and personnel for assistance. I.R.-V. is funded by FJC2021-048099-I funded by MCIN/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR. D.M. is funded by grant PRE2020-092578 MCIN/AEI/10.13039/501100011033. M.G. is funded by beca de formación de profesorado Universitario fellowship 20/01418. M.F.-M. is funded by INPhINIT Retaining 2024 from Caixa Foundation LCF/BQ/DR24/12080010. A.R.-U. is supported by Community of Madrid (PIPF-2022/SALGL-24581). R.B.-R. is funded by Beca de Formación de Profesorado Universitario Fellowship 20/03365. A. Devesa is scientifically supported by the Thrasher Research Fund and acknowledges the support of Sociedad Española de Cardiología (grant SEC/PRS-MOV-INT20/002). Work in the D.S. laboratory is funded by the CNIC; the European Union’s Horizon 2020 Research and Innovation Program under grant agreement ERC-2016-Consolidator Grant 725091; Ministerio de Ciencia, Innovación y Universidades (MICIU) PID2022-137712OB-I00, CPP2021-008310 and CPP2022-009762 MICIU/AEI/10.13039/501100011033 Agencia Estatal de Investigación, Unión Europea NextGenerationEU/PRTR; Comunidad de Madrid (P2022/BMD-7333 INMUNOVAR-CM); Scientific Foundation of the Spanish Association Against Cancer (AECC- PRYGN246642SANC); Worldwide Cancer Research WWCR-25-0080; European Union ERC-2023-PoC; a research agreement with Inmunotek S.L.; and la Caixa Foundation (LCF/PR/HR23/52430012 and LCF/PR/HR22/52420019). Work in the B.I. laboratory is supported by the European Commission (H2020-HEALTH 945118 and ERC-CoG 819775); the PID2022-140176OB-I00, PID2019-107332RB-I00 MCIN/AEI /10.13039/501100011033; and the Comunidad de Madrid RENIM P2022/BMD-7403. F.B. is funded by grants from the Swedish Heart Lung Foundation (20240882) and is a Wallenberg Fellow and recipient of an ERC-Advanced grant 2022 (101096705-IMPACT). K. Stellos was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation — Project ID 394046768 — SFB1366 ‘Vascular control of organ function’ C07), the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (MODVASC, grant agreement 759248), the German Centre for Cardiovascular Research (DZHK) and the Helmholtz-Institute for Translational AngioCardioScience (HI-TAC) of the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) at Heidelberg University, Heidelberg, Germany. Metabolomics Workbench is supported by NIH grant U2C-DK119886 and OT2-OD030544 grants. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the MICIU and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MICIU/AEI /10.13039/501100011033). The PESA study is funded by the CNIC and Santander Bank. This study was partially funded by an intramural grant CNIC-Severo Ochoa to B.I. and D.S., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001041-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A type I interferon-mitochondrial axis regulates efferocytosis and interferon-stimulated gene induction in macrophages

  • Dunphy, Gillian
  • Adán-Barrientos, Irene
  • Fernández-Delgado, Irene
  • Villarroya-Beltri, Carolina
  • Heras-Murillo, Ignacio
  • Moya-Ruiz, Elena
  • Sánchez-Álvarez, Miguel
  • Jarit-Cabanillas, Aitor
  • del Pozo, Miguel A.
  • Guerra, Susana
  • Sánchez-Madrid, Francisco
  • Sancho, David
Macrophage metabolism is intricately linked to cellular function. Contrasting with Toll-like receptor (TLR) stimulation, cytosolic nucleic acid sensing induced a decrease in mitochondrial membrane potential (MMP) while maintaining mitochondrial respiration. Interferon α/β (IFN-I) receptor (IFNAR) signaling was necessary and sufficient for this metabolic response. IFNAR signaling induced interferon-stimulated gene 15 (ISG15) expression and ISGylation of mitochondrial proteins, including subunits of mitochondrial complex V, increasing ATP production and decreasing MMP, thus enhancing macrophage efferocytic capacity. Moreover, the IFNAR-ISG15-mediated drop in MMP activated the mitochondrial protease OMA1, inducing mitochondrial fission and decreasing endoplasmic reticulum-mitochondria communication, thus dampening IFN-stimulated gene (ISG) induction. Loss of ISG15 or OMA1 enhanced histone acetylation and ISG induction upon IFN-I stimulation, in a manner dependent on mitochondrial calcium uptake. This increase in ISG induction provided protection against acute viral infections. These data indicate that IFNAR-ISG15 signaling boosts efferocytosis while limiting ISG induction, thereby promoting the resolution of inflammation., The D.S. laboratory received support from the CNIC; the Ministerio de Ciencia, Innovación y Universidades (MICIU) (PID2022-137712OB-I00, CPP2021-008310, CPP2022-009762, and CPP2024-011365); MICIU/AEI/10.13039/501100011033 Agencia Estatal de Investigación, Unión Europea NextGenerationEU/PRTR; Comunidad de Madrid (P2022/BMD-7333 INMUNOVAR-CM); the Scientific Foundation of the Spanish Association Against Cancer (AECC-PRYGN246642SANC); Worldwide Cancer Research (WWCR-25-0080); Fundación CRIS contra el cáncer (excellence2025_03); the European Union (ERC-2023-PoC GA-101158245-ImnovAth); and the “La Caixa” Foundation (LCF/PR/HR23/52430012 and LCF/PR/HR22/52420019). M.A.d.P. acknowledges support from the Spanish Ministry of Science, Innovation & Universities (MICIU)/Agencia Estatal de Investigación (AEI)/FEDER (PID2023-146414OB-I00/AEI/10.13039/501100011033); from ERDF/EU; and from the Comunidad de Madrid (TecNanoBio-CM, ref. TEC-2024/TEC-158). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 892965. G.D. is supported by a European Molecular Biology Organization Long-term Fellowship ALTF 379-2019. I.A.-B. is supported by a Beca de Formación del Profesorado Universitario (FPU) fellowship (FPU18/05752). I.H.-M. is supported by a La Caixa INPhINIT fellowship (ID 100010434, fellowship code: LCF/BQ/IN17/11620074). E.M.-R. is a recipient of support from the Comunidad Autonoma de Madrid (PIPF-2023/SAL-GL-29932). A.J.-C. is supported by a Beca de Formación del Profesorado Universitario (FPU) fellowship (FPU18/05434). M.S.-A. is supported by the MICIU (RYC2020-029690-I and PID2021-128106NA-I00). Flow cytometry was conducted at the CNIC Flow Cytometry Unit. Microscopy was conducted at Microscopy & Dynamic Imaging, CNIC. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the MICIU, and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MICIU/AEI /10.13039/501100011033).